Intrinsiqs

Is BioMarin Pharmaceutical Inc. overvalued?

BioMarin Pharmaceutical Inc. (BMRN) looks overvalued — trading about 12% above its fair value.

Overvalued
Current price $69.17 Fair value $60.86
Price
$69.17
Fair value
$60.86
Current P/E
33.3
Normal P/E
29.3
Market cap
$13.37B
Dividend yield
0.0%
Return on equity
1.2%
Sector
Healthcare

See the full interactive analysis →

Fair value compares BMRN's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.

Related stocks

LLY Eli Lilly and CompanyJNJ Johnson & JohnsonABBV AbbVie Inc.UNH UnitedHealth Group IncorporatedRHHBY Roche Holding AGMRK Merck & Co., Inc.